Abstract
Myeloperoxidase (MPO) cytochemical activity, recognized as a very important hallmark of myeloblasts, is generally negative in chronic myeloid leukemia (CML) blast crisis (BC). Because this finding is unexpected, being not in keeping with the myeloproliferative nature of CML, we tried to ascertain if MPO cytochemical negativity could be an intrinsic property of blasts of CML and hence present in the preblastic phases as well. Myeloperoxidase cytochemistry of peripheral blood blasts in 161 cases of CML, including 103 in chronic phase (CP) and 29 each in accelerated phase (AP) and BC, was assessed and compared with that of 30 cases of acute myeloid leukemia, AML-M2. Blasts of 97 (94.2%) of 103 cases of CP, 28 (96.6%) of 29 cases of AP, and 22 (75.9%) of 29 cases of BC were negative for MPO (<3% MPO-positive blasts). Compared with the strong MPO positivity, both in terms of intensity and proportion, in the AML-M2 cases, the positivity in the CML cases was generally weak and was seen in a small number of blasts (5–15%), except in one case of BC with 20% positive blasts. Absence or, at times, weak MPO cytochemical activity is an intrinsic property of blasts of all phases of CML, and use of the term myeloblast in CML should be understood to refer to a cell with this property. This also explains why MPO cytochemistry, despite its high reputation as a myeloid-lineage marker, generally does not help in CML BC. CML BC should therefore be considered as a possible diagnosis along with acute lymphoblastic leukemia, AML-M0, AML-M7, etc., in the setting of MPO-negative blasts. Similarity between MPO expression pattern in CML, i.e., negative in blasts and positive in the more mature cells, and that during maturation of normal myeloid series of cells shows the deranged myelopoiesis of CML to be undisturbed at least with respect to MPO expression. There is need for a more comprehensive study of blasts of preblastic phases.
Similar content being viewed by others
References
Childs CG, Stass SA (1987) Introduction. Characterization and diagnosis of the acute leukemias. In: Stass SA (ed) The acute leukemias. Biologic, diagnostic and therapeutic determinants. Marcel Dekker, New York, pp 1–26
Peffault de Latour RP, Legrand O, Moreau D, Perrot JY, Blanc CM, Chaoui D, Casadevall N, Marie JP (2003) Comparison of flow cytometry and enzyme cytochemistry for the detection of myeloperoxidase in acute myeloid leukaemia: interests of a new positivity threshold. Br J Haematol 122:211–216
Bene MC, Castoldi G, Knapp W, Ludwig WD, Matutes E, Orfao A, van’t Veer MB (1995) Proposals for the immunological classification of acute leukemias. European group for the immunological characterization of leukemias (EGIL). Leukemia 9:1783–1786
Vardiman JW, Pierre R, Thiele J, Imbert M, Brunning RD, Flandrin G (2001) Chronic myelogenous leukemia. In: Jaffe ES, Harris NL, Stein H, Vardiman JW (eds) Pathology and genetics of tumours of haematopoietic and lymphoid tissues. IARC, Lyon, pp 20–26
Anastasi J, Vardiman JW (2000) Chronic myelogenous leukemia and the chronic myeloproliferative diseases. In: Knowles DM (ed) Neoplastic hematopathology. Lippincott Williams and Wilkins, Philadelphia, pp 1745–1790
Peterson LC, Bloomfield CD, Brunning RD (1976) Blast crisis as an initial or terminal manifestation of chronic myeloid leukemia. A study of 28 patients. Am J Med 60:209–220
Catovsky D, O’Brien M, Cherchi M, Benavides I (1978) Ultrastructural, cytochemical and surface marker analysis of cells during blast crisis of chronic granulocytic leukaemia. Boll Ist Sieroter Milan 57:344–354
Vardiman JW, Coelho A, Golomb HM, Rowley J (1983) Morphologic and cytochemical observations on the overt leukemic phase of therapy-related leukemia. Am J Clin Pathol 79:525–530
Saikia T, Advani S, Dasgupta A, Ramakrishnan G, Nair C, Gladstone B, Kumar MS, Badrinath Y, Dhond S (1988) Characterization of blast cells during blastic phase of chronic myeloid leukemia by immunophenotyping—experience in 60 patients. Leuk Res 12:499–506
Karnik MP, Nair CN, Zingde SM, Gothoskar BP, Zachariah L, Barbhaya S, Advani SH (1994) Use of polyclonal anti-myeloperoxidase antibody in myeloid lineage determination. Indian J Med Res 100:272–276
Hughes TP, Goldman JM (1990) Chronic myeloid leukemia. In: Hoffman R, Benz EJ Jr, Shattil SJ, Furie B, Cohen HJ, Hughes TP, Goldman JM (eds) Hematology: basic principles and practice. Churchill Livingstone, New York, pp 854
International Committee for Standardization in Haematology (ICSH) (1985) Recommended methods for cytological procedures in haematology. Clin Lab Haematol 7:55–74
Rosenthal S, Canellos GP, DeVita VT, Gralnick HR (1977) Characteristics of blast crisis in chronic granulocytic leukemia. Blood 49:705–714
Farber S, Diamond LK, Mercer RD, Sylvester RF Jr, Wolff JA (1948) Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-gultamic acid (aminopterin). N Engl J Med 238:787–793
Mauer AM (1990) Clinical features of human leukemia. In: Mauer AM (ed) The biology of human leukemia. The Johns Hopkins University Press, Baltimore, pp 1–22
Bennett JM (1990) The diagnosis of acute and chronic leukemias: morphologic consideration. In: Mauer AM (ed) The biology of human leukemia. The Johns Hopkins University Press, Baltimore, pp 23–43
Rabinowitz I, Larson RS (2004) Chronic myeloid leukemia. In: Greer JP, Foerster J, Lukens JN, Rodgers GM, Paraskevas F, Glader B (eds) Wintrobe’s clinical hematology, Lippincott Williams and Wilkins, Philadelphia, pp 2235–2258
Brunning RD, McKenna RW (1994) Tumors of the bone marrow. Armed Forces Institute of Pathology, Washington, DC, pp 195–254
Bettelheim P, Lutz D, Majdic O, Paietta E, Haas O, Linkesch W, Neumann E, Lechner K, Knapp W (1985) Cell lineage heterogeneity in blast crisis of chronic myeloid leukaemia. Br J Haematol 59:395–409
Polli N, O’Brien M, Tavares de Castro J, Matutes E, San Miguel JF, Catovsky D (1985) Characterization of blast cells in chronic granulocytic leukaemia in transformation, acute myelofibrosis and undifferentiated leukaemia. I. Ultrastructural morphology and cytochemistry. Br J Haematol 59:277–296
San Miguel JF, Tavares de Castro J, Matutes E, Rodriguez B, Polli N, Zola H, McMichael AJ, Bollum FJ, Thompson DS, Goldman JM, Catovsky D (1985) Characterization of blast cells in chronic granulocytic leukaemia in transformation, acute myelofibrosis and undifferentiated leukaemia. II. Studies with monoclonal antibodies and terminal transferase. Br J Haematol 59:297–309
Armitage FL (1939) A modified peroxidase stain for blood and bone marrow films. Pathol Bacteriol 49:579–581
Brederoo P, van der Meulen J, Daems WT (1986) Ultrastructural localization of peroxidase activity in developing neutrophils, granuloyctes from human bone marrow. Histochemistry 84:445–453
Marmont AM, Damasio E, Zucker-Frunklin D (1988) Neutrophils. In: Zucker-Franklin D, Greaves MF, Grossi CE, Marmont AM (eds) Atlas of blood cells. Function and pathology. Lea & Febiger, Philadelphia, pp 159–161
Bainton DF, Ullyot JL, Farquhar MG (1971) The development of neutrophilic polymorphonuclear leukocytes in human bone marrow. Origin and content of azurophil and specific granules. J Exp Med 134:907–934
Terstappen LWMM, Safford M, Loken MR (1990) Flow cytometric analysis of human bone marrow III. Neutrophil maturation. Leukemia 4:657–663
Koeffler HP, Ranyard J, Pertcheck (1985) Myeloperoxidase: its structure and expression during myeloid differentiation. Blood 65:484–491
Tobler A, Miller CW, Johnson KR, Selsted ME, Rovera G, Koeffler HP (1988) Regulation of gene expression of myeloperoxidase during myeloid differentiation. J Cell Physiol 136:215–225
Lubbert M, Herrmann F, Koeffler HP (1991) Expression and regulation of myeloid—specific genes in normal and leukemic myeloid cells. Blood 77:909–924
Strobl H, Takimoto M, Majdic O, Fritsch G, Scheinecker C, Hocker P, Knapp W (1993) Myeloperoxidase expression in CD34+ normal human hematopoietic cells. Blood 82:2069–2078
Scholz W, Platzer, Schumich A, Hocher B, Fritsch G, Knapp W, Strobl H (2004) Initial human myeloid/dendritic cell progenitors identified by absence of myeloperoxidase protein expression. Exp Hematol 32:270–276
Lichtman MA (1995) Chronic myelogenous leukemia and related disorders. In: Beutler E, Lichtman MA, Coller BS, Kipps TJ (eds) Hematology. McGraw-Hill, New York, pp 298
Vainchenker W, Villeval JL, Tabilio A, Matamis H, Karianakis G, Guichard J, Henri A, Vernant JP, Rochant H, Breton-Gorius J (1988) Immunophenotype of leukemic blasts with small peroxidase-positive granules detected by electron microscopy. Leukemia 2:274–281
Koeffler HP, Golde DW (1978) Acute myelogenous leukemia: a human cell line responsive to colony-stimulating activity. Science 200:1153–1154
Koeffler HP, Billings R, Lusis AJ, Sparkes R, Golde DW (1980) An undifferentiated variant derived from the human acute myelogenous leukemia cell line (KG-1). Blood 56:265–273
Bain BJ (1999) Leukemia diagnosis, 2nd edn. Blackwell Science Ltd, Oxford
Martin-Henao GA, Quiroga R, Sureda A, Garcia J (1999) CD7 expression on CD34+ cells from chronic myeloid leukaemia in chronic phase. Am J Hematol 61:178–186
Schmetzer HM, Gehartz HH (1997) Immunological classification of chronic myeloid leukemia distinguishes chronic phase, imminent blastic transformation and acute lymphoblastic leukemia. Exp Hematol 25:502–508
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Anand, M., Ghara, N., Kumar, R. et al. Myeloperoxidase cytochemical negativity: an unexpected but intrinsic property of blasts of all phases of chronic myeloid leukemia. Ann Hematol 84, 767–770 (2005). https://doi.org/10.1007/s00277-005-1056-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00277-005-1056-y